BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
BioNTech and Australia’s State of Victoria will establish an mRNA research and innovation center to strengthen translational research for innovative medicines from discovery to delivery.
State of Victoria in Australia and BioNTech SE have signed a Letter of Intent to collaborate on the research and development of potential mRNA-based vaccines and therapies. A research and innovation center will be established in Melbourne as part of the partnership to facilitate the transition from academic to clinical research.
The company plans to build a clinical scale end-to-end mRNA manufacturing facility in Melbourne based on its BioNTainer solution to support product development, manufacturing, and clinical testing. In addition to being part of BioNTech’s global network, the facility is expected to attract researchers locally, regionally, and internationally.
“Science and innovation can only make a difference if it is applied outside of the laboratories and reaches people worldwide. This partnership is a major step forward to enable access to mRNA technology and promote collaborations in the Asia-Pacific region,” said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Australia provides excellent academic research, and we are looking forward to collaborating with world-class scientists and researchers to strengthen Australia’s mRNA ecosystem and to jointly develop potential novel treatments and vaccines for people worldwide.”
As part of this collaboration, with the aim to support Australia’s mRNA ecosystem by curating projects and to determine their potential transition into preclinical and clinical development, the State of Victoria and BioNTech will establish a research and innovation center, directed in partnership with the State, supported by BioNTech’s advice and know-how. The partnership will also include the research and development of experimental therapies including mRNA-based product candidates for indications with high unmet medical need, for instance in oncology. BioNTech will support the R&D efforts on a project-by-project basis with the Company’s expertise in mRNA research and clinical development of potential new products.
“We at BioNTech are committed to global public health, and as we continue to expand internationally, we look forward to working jointly to drive the development of innovative medicines,” said Dr. Sierk Poetting, COO of BioNTech. “Our BioNTainers are designed as turnkey manufacturing sites for mRNA-based medicines and product candidates. In Melbourne, our BioNTainers will allow for an end-to-end production including fill and finish for clinical-scale manufacturing of mRNA candidates, once approved.”
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.